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Surgical treatment of stage IIIA non-small cell lung cancer 
(NSCLC) remains a controversial area in the management 
of lung cancer despite being considered as part of 
combined modality therapy over the last two decades (1). 
The heterogeneity of stage III disease and the need for a 
multidisciplinary approach adds complexity to the treatment 
of resectable stage III NSCLC. Prospective randomized 
trials including surgery have consistently faced problems 
in recruiting. Multicenter trials in different countries: the 
United Kingdom (2), USA (3), France (4) or Japan (5) were 
terminated early as a result of poor accrual. This may in part 
be due to the low frequency of suitable patients for surgical 
treatment. Two modern randomized studies have been 
published comparing concurrent chemoradiotherapy (CRT) 
treatments with and without surgery. In the Intergroup 
0139 trial (6), patients with stage III N2 disease were treated 
with concurrent induction chemotherapy plus radiotherapy. 
If no progression occurred, patients in the surgical group 
underwent resection and those in the chemoradiation group 
continued radiotherapy. A total of 396 eligible patients 
were randomized and there were no differences in overall 
survival (OS) between the two groups. However, in an 
exploratory analysis, survival was improved for the patients 
who underwent lobectomy, but not pneumonectomy, 
compared with definitive concurrent chemoradiation. In 
the ESPATUE trial (7) patients with resectable stage IIIA 
N2 and selected stage IIIB NSCLC were randomized to 
surgery or definitive concurrent CRT boost after induction 
chemotherapy followed by concurrent CRT. A total of 245 
eligible patients were recruited to induction therapy over 
a 10-year period, 161 of them were finally randomized to 
surgery or tailored dose-scaled CRT. It should be pointed 
out that 63% of those patients were stage IIIB. There was 
no difference in OS between the arms. Although both trials 
were planned to demonstrate superiority in the surgery 
arm, they failed to show any benefit from surgery in terms 
of OS. Consequently, definitive concurrent CRT is the only 
strategy which can be given category 1 recommendation for 
most stage III NSCLC patients. 
The induction strategy for patients with stage III 
NSCLC who are deemed candidates for surgery is not 
well established. There is controversy on the benefit of the 
addition of radiation therapy to chemotherapy as part of 
induction therapy before surgery. Two large randomized 
phase III trials performed in Europe evaluate this issue. 
The German Lung Cancer Cooperative Group (8) 
randomized 524 stage IIIA/IIIB el igible NSCLC 
patients (36% of whom were T4N2 or TanyN3) to an 
induction treatment of sequential chemotherapy and 
concurrent CRT or to chemotherapy alone. Fifty four 
percent of the patients in the interventional group 
underwent resection versus 59% in the control group, 
but only 37% and 34% respectively, underwent complete 
resection. The addition of CRT to preoperative treatment 
resulted in an increase in pathological response rate 
(60% vs. 20%) and mediastinal downstaging (49% vs. 29%) 
in those patients completely resected but did not improve 
either disease-free survival (DFS), which was the primary 
end-point (median DFS: 9.5 vs. 10.0 months), or OS (median 
OS: 15.7 vs. 17.6 months). In another study the Swiss 
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Lung Cancer Project Group (9) randomized 232 patients 
with pathologically proven stage IIIA N2 NSCLC over an 
11-year period. Patients were randomly assigned preoperative 
chemotherapy and sequential radiotherapy or preoperative 
chemotherapy alone. Eighty five percent of the patients 
in the interventional group and 82% in the control group 
underwent surgery. Complete resection, nodal downstaging 
and pathologic complete response were achieved in a similar 
proportion of patients who underwent surgery in the two 
groups (91% and 81%; 64% and 53% and 16% and 12%). 
There was no statistically significant difference in event-free 
survival (median EFS: 12.8 vs. 11.6 months) or OS (median 
OS: 37.1 vs. 26.2 months; HR =1.0) between the two 
induction treatments. Therefore, the survival benefit 
of the addition of radiation therapy to chemotherapy 
before surgery has not been substantiated in randomized 
controlled trials. A recent meta-analysis (10) involving 
2,724 patients from 12 studies also showed that neoadjuvant 
chemoradiation (NCRT) improved pathological response 
and mediastinal tumor downstaging when compared with 
neoadjuvant chemotherapy alone in patients with resectable 
stage III NSCLC but could not demonstrate an increase in 
progression-free survival or OS.
Another meta-analysis (11) included 868 patients from 
six randomized controlled trials and compared definitive 
concurrent CRT to induction chemotherapy or concurrent 
CRT followed by surgery (bimodal or trimodal therapy) in 
patients with N2 disease. The HR for patients randomized 
to surgery after CRT was 0.87 (0.75–1.01, P=0.068), 
showing a survival benefit for trimodal therapy that did not 
reach the statistical level of significance. 
Although in all patients with stage III considered for an 
induction approach followed by surgery it is imperative to 
obtain a pre-treatment surgical opinion on resectability, in 
some of these patients ultimately surgery becomes unfeasible. 
The probability of this event favors induction CRT over 
induction chemotherapy alone, since these patients will not 
have received local treatment and the delivery of adequate 
definitive CRT at this juncture may be compromised by the 
prior chemotherapy. Moreover, the optimal postoperative 
management of patients treated with bimodal or trimodal 
therapy has not been prospectively studied. In the majority 
of prospective randomized trials of induction chemotherapy, 
a high percentage of patients receive PORT, but there are no 
comparative data supporting its role.
The Intergroup 0139 trial (6) has been the base of 
current clinical practice with trimodal therapy for patients 
who present with stage IIIA N2 with limited or one level 
mediastinal disease and can be treated with a lobectomy, 
and this has been the preferred approach in this setting (12). 
The optimal t ime interval  from completion of 
chemoradiation therapy to surgery has not been established. 
The development of pulmonary injury associated with 
neoadjuvant concurrent CRT may result in early and late 
morbidity from surgery. The interval to surgery (ITS) 
following induction concurrent CRT has been empirically 
established as 4–6 weeks, short enough to reduce the 
likelihood of having developed pneumonitis or fibrosis at 
the time of surgery, but with a necessary interval of recovery 
to enable the patient to undergo surgery.
Gao et al. (13) studied the influence of different time 
intervals on the outcome of patients with stage IIIA N2 
NSCLC and concluded that a time interval longer than 
6 weeks was detrimental in terms of OS. The study was 
based on the National Cancer Data Base (NCDB), where 
they identified 1,623 patients with stage IIIA N2 NSCLC 
who underwent NCRT followed by surgery between 
2004 and 2012. They categorized the study cohort in four 
intervals in weeks (from 0 to 12 weeks) between completion 
of NCRT (end of radiotherapy) and surgery: ITS quartiles. 
Median OS decreased significantly in the 9–12-week 
interval in the univariate analysis compared to the 0–3-
week interval, and for both the 6–9-week interval and the 
9–12-week interval in the multivariate analysis, which 
was adjusted for the surgical procedure (pneumonectomy 
or lobectomy) and radiation therapy dose, among other 
prognostic factors. Interestingly, there was no difference in 
30 day-mortality between the first quartile and the other 
three, but there was a non-significant increase in 90-day 
mortality in patients with an ITS greater than 6 weeks.
 This is the first study demonstrating a negative impact of 
prolonged ITS on survival, and advices against unnecessary 
delays in surgery. The results of this study should be 
interpreted with caution due to its retrospective nature 
which does not allow to control the selection in treatment 
allocation. In addition there is a lack of information on 
some tumor and treatment factors, as the mediastinal 
tumor burden or type and intensity of chemotherapy. 
These unknown variables may not be balanced among time 
interval groups. 
Management of stage IIIA NSCLC continues to be 
challenging, there are no definitively proven optimal 
approaches and treatment selection in a multidisciplinary 
conference is of paramount importance. As we will not 
be able to rely on randomized controlled data to obtain 
evidence for every relevant detail of the complex trimodality 
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approach we will need to learn from large retrospective 
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